In last trading session, Eterna Therapeutics Inc (NASDAQ:ERNA) saw 0.58 million shares changing hands with its beta currently measuring 4.49. Company’s recent per share price level of $0.31 trading at -$0.03 or -7.08% at ring of the bell on the day assigns it a market valuation of $16.18M. That closing price of ERNA’s stock is at a discount of -745.16% from its 52-week high price of $2.62 and is indicating a premium of 29.03% from its 52-week low price of $0.22.

Eterna Therapeutics Inc (NASDAQ:ERNA) trade information

Upright in the red during last session for losing -7.08%, in the last five days ERNA remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $0.31 price level, adding 16.17% to its value on the day. Eterna Therapeutics Inc’s shares saw a change of 7.11% in year-to-date performance and have moved 9.42% in past 5-day. Eterna Therapeutics Inc (NASDAQ:ERNA) showed a performance of -50.42% in past 30-days.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.06% during past 5 years.

On the other hand, Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 214.1 shares of worth $67420.0 or 0.42% of the total outstanding shares. The later fund manager was in possession of 26.1 shares on Sep 30, 2024 , making its stake of worth around $8218.0 in the company or a holder of 0.05% of company’s stock.